PolyPid Ltd.

Contributing Author

Recent Articles by PolyPid Ltd.

Jun-16	PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results PYPD GlobeNewswire
Jun-09	PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints PYPD GlobeNewswire
Jun-06	PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 PYPD GlobeNewswire
May-20	PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 PYPD GlobeNewswire
May-14	PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PYPD GlobeNewswire